以代谢为目标的治疗性低温优化脑代谢可降低重型颅脑创伤死亡率
该单盲随机对照试验纳入88例重型颅脑创伤患者(格拉斯哥昏迷评分3~8分),随机分为代谢目标低温治疗组(MTHT,以静息代谢率50%~60%为低温目标)和体温目标低温治疗组(BTHT,以体温32°C~35°C为低温目标),各44例。主要终点死亡率在MTHT组显著低于BTHT组(15.91% vs 34.09%,p=0.049)。嵌套代谢组学分析纳入MTHT组8例和BTHT组6例,显示第7天MTHT组脑与循环代谢模式存在显著差异,并鉴定出潜在的神经保护监测代谢物。作者认为MTHT可显著降低重型颅脑创伤患者死亡率,并建议将代谢率降至50%~60%作为低温治疗目标。
要点
- 重型颅脑创伤(GCS 3~8分)患者以静息代谢率50%~60%为目标行低温治疗,死亡率15.91%,低于体温目标32°C~35°C组的34.09%(p=0.049)。
- 该单盲随机对照试验自2013年12月至2014年12月共纳入并分析88例,MTHT组与BTHT组各44例,中位年龄42岁,男性69.32%,平均GCS 6.17±1.02。
- 嵌套代谢组学分析纳入MTHT组8例、BTHT组6例,第7天MTHT组脑与循环代谢模式基于模型参数和得分图显示显著差异。
- 代谢组学鉴定出可用于低温治疗神经保护监测的潜在代谢物指标。
- 作者认为将代谢率降至50%~60%应设为低温治疗目标。
适用人群与场景
- 重型颅脑创伤患者,格拉斯哥昏迷评分3~8分。
- 研究自2013年12月至2014年12月纳入并分析88例,MTHT组与BTHT组各44例。
诊断标准与关键阈值
- MTHT组低温治疗目标为静息代谢率50%~60%。
- BTHT组低温治疗目标为体温32°C~35°C。
处置流程与药物剂量
- MTHT组:以静息代谢率50%~60%作为低温治疗目标。
- BTHT组:以体温32°C~35°C作为低温治疗目标。
- 低温治疗期间于基线及第1、3、7天采集脑与循环代谢池血样(从MTHT和BTHT组中随机选取亚组)。
研究设计与关键结果
- 单盲随机对照试验,88例重型颅脑创伤患者,MTHT组44例与BTHT组44例,中位年龄42岁,男性69.32%,平均GCS 6.17±1.02。
- 主要终点死亡率:MTHT组15.91% vs BTHT组34.09%(p=0.049),MTHT组显著低于BTHT组。
- 嵌套代谢组学分析纳入MTHT组8例和BTHT组6例,基于模型参数和得分图,第7天MTHT组脑与循环代谢模式显示显著差异。
- 通过氢核磁共振代谢组学鉴定出代表低温治疗潜在神经保护监测参数的代谢物。
证据类型、等级与局限
- 证据类型:单盲随机对照试验(治疗性研究,证据等级Level I)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为MTHT可显著降低重型颅脑创伤患者死亡率,并将代谢率降至50%~60%设为低温治疗目标。
- 代谢组学结果显示该策略可有效改善脑代谢。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Therapeutic hypothermia is widely used to treat traumatic brain injuries (TBIs). However, determining the best hypothermia therapy strategy remains a challenge. We hypothesized that reducing the metabolic rate, rather than reaching a fixed body temperature, would be an appropriate target because optimizing metabolic conditions especially the brain metabolic environment may enhance neurologic protection. A pilot single-blind randomized controlled trial was designed to test this hypothesis, and a nested metabolomics study was conducted to explore the mechanics thereof.
METHODS: Severe TBI patients (Glasgow Coma Scale score, 3-8) were randomly divided into the metabolic-targeted hypothermia treatment (MTHT) group, 50% to 60% rest metabolic ratio as the hypothermia therapy target, and the body temperature-targeted hypothermia treatment (BTHT) control group, hypothermia therapy target of 32°C to 35°C body temperature. Brain and circulatory metabolic pool blood samples were collected at baseline and on days 1, 3, and 7 during the hypothermia treatment, which were selected randomly from a subgroup of MTHT and BTHT groups. The primary outcome was mortality. Using H nuclear magnetic resonance technology, we tracked and located the disturbances of metabolic networks.
RESULTS: Eighty-eight severe TBI patients were recruited and analyzed from December 2013 to December 2014, 44 each were assigned in the MTHT and BTHT groups (median age, 42 years; 69.32% men; mean Glasgow Coma Scale score, 6.17 ± 1.02). The mortality was significantly lower in the MTHT than the BTHT group (15.91% vs. 34.09%; p = 0.049). From these, eight cases of MTHT and six cases from BTHT group were enrolled for metabolomics analysis, which showed a significant difference between the brain and circulatory metabolic patterns in MTHT group on day 7 based on the model parameters and scores plots. Finally, metabolites representing potential neuroprotective monitoring parameters for hypothermia treatment were identified through H nuclear magnetic resonance metabolomics.
CONCLUSION: MTHT can significantly reduce the mortality of severe TBI patients. Metabolomics research showed that this strategy could effectively improve brain metabolism, suggesting that reducing the metabolic rate to 50% to 60% should be set as the hypothermia therapy target.
LEVEL OF EVIDENCE: Therapeutic study, Level I.
参考来源
- Feng JZ, Wang WY, Zeng J, et al. Optimization of brain metabolism using metabolic-targeted therapeutic hypothermia can reduce mortality from traumatic brain injury. J Trauma Acute Care Surg. 2017. PMID: 28452885. doi:10.1097/TA.0000000000001522
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。